ProShare Advisors
PVLA

ProShare Advisors’s Palvella Therapeutics PVLA Stock Holding History

ProShare Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-177
Closed -$36K – 2413
2021
Q1 		$36K Buy
177
+30
+20% +$6.56K ﹤0.01% 2243
2020
Q4 		$29K Buy
+147
New +$30.6K ﹤0.01% 2077

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ProShare Advisors's PVLA Position: Q2 2021 in Review

ProShare Advisors sold out of Palvella Therapeutics (PVLA) in Q2 2021, closing a stake of 177 shares — an estimated $36K sold.

ProShare Advisors first reported a position in PVLA in Q4 2020 and held it in 2 quarters. The position peaked at $36K in Q1 2021. 73 funds tracked by Wall St. Rank hold PVLA as of Q2 2021.

  • ProShare Advisors reported no remaining Palvella Therapeutics position as of Q2 2021 after selling out during the quarter.
  • ProShare Advisors sold 177 Palvella Therapeutics shares in Q2 2021, an estimated $36K.
  • ProShare Advisors first reported a position in Palvella Therapeutics in Q4 2020 and held it in 2 quarters.
  • ProShare Advisors's Palvella Therapeutics position peaked at $36K in Q1 2021.
  • 73 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2021.

Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.